Results
Eckert & Ziegler will supply Actinium-255 to VUB spin-off Precirix
VUB spin-off Precirix, the clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, discloses that they signed an agreement with Eckert & Ziegler for the supply of Actinium-225. Actinium-225 is used as an active substance in cancer treatment.
Read more
Emission-free parcel deliveries in Brussels
Over the next three years, VUB Mobilise and bpost will join forces toward a zero-carbon energy future. The goal of this project is to support bpost in the shift towards zero emission parcel deliveries in Brussels.
Read more
ACTIVE-AGE@home: a home-based functional exercise program for community-dwelling frail older adults
Unfortunately, some applied research projects within the biomedical field do not reach the patient due to a lack of industrial interest.
Read more
FOR FUTURE ENTREPRENEURS
Read more
39M euro invested in VUB spin-off eTheRNA to boost mRNA therapeutics
mRNA leading expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers invest in EUR 39M Series B2 financing of mRNA technology platform company eTheRNA to expand its expertise and capabilities as a one-stop service to bring RNA-based research and products from the lab to the clinic.
Read more
PIANISSIMO: Opioid detoxification for patients with Persistent Spinal Pain Syndrome Type II
Unfortunately, some applied research projects within the biomedical field do not reach the patient due to a lack of industrial interest.
Read more
Hugo Thienpont remains vice-rector Innovation & Industry Relations of VUB
We are very pleased that our new rector Jan Danckaert has chosen to prolong the mandate of Hugo Thienpont as vice-rector Innovation and Industry Relations, so that he can continue to pursue his policy.
Read more
Prenatal valaciclovir-treatment for congenital CMV (Cytomegalovirus)
Unfortunately, some applied research projects within the biomedical field do not reach the patient due to a lack of industrial interest.
Read more
INSTA-MD: Inflammation-based Stratification for immune-Targeted Augmentation in Major Depressive disorder
Unfortunately, some applied research projects within the biomedical field do not reach the patient due to a lack of industrial interest.
Read more
Weave.ly, a VUB spin-off, completes first capital round
Weave.ly, a VUB spin-off, has completed a first capital round of € 300.000. The capital round was led by interuniversity seed and growth fund Qbic and completed by finance&invest.brussels. Weave.ly developed a pioneering no-code platform that allows for partial software...
Read more